iPSC-RPE
/ Beijing Tongren Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 17, 2026
Wnt signaling dysregulation drives Stargardt disease pathogenesis.
(PubMed, Sci China Life Sci)
- "Using patient-derived iPSC-RPE harboring distinct ABCA4 mutations, we demonstrate that ABCA4 loss disrupts RPE hexagonal morphology, reduces pigmentation, and aberrantly activates neural retinal differentiation...Our work positions non-canonical Wnt agonism as a therapeutic strategy for Stargardt and underscores the broader imperative for mutation-tailored interventions in inherited retinal diseases. By revealing phenotypic convergence on Wnt signaling dysregulation in ABCA4-deficient RPE, this study provides a framework for understanding epithelial-pathway-driven degeneration, with implications for AMD, fibrosis, and developmental disorders characterized by polarity loss."
Journal • Age-related Macular Degeneration • CNS Disorders • Developmental Disorders • Fibrosis • Immunology • Inherited Retinal Dystrophy • Macular Degeneration • Ophthalmology • Psychiatry • Retinal Disorders
July 06, 2022
Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: Beijing Tongren Hospital
New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Transplantation • Wet Age-related Macular Degeneration
1 to 2
Of
2
Go to page
1